Human Neonatal Rotavirus Vaccine (RV3-BB) Produces Vaccine Take Irrespective of Histo-Blood Group Antigen Status.
Lewis antibodies
RV3-BB
Rotavirus
histo-blood group antigens
neonatal vaccination
secretor status
vaccine take
Journal
The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675
Informations de publication
Date de publication:
16 03 2020
16 03 2020
Historique:
received:
06
05
2019
accepted:
03
07
2019
pubmed:
26
11
2019
medline:
5
1
2021
entrez:
26
11
2019
Statut:
ppublish
Résumé
VP4 [P] genotype binding specificities of rotaviruses and differential expression of histo-blood group antigens (HBGAs) between populations may contribute to reduced efficacy against severe rotavirus disease. P[6]-based rotavirus vaccines could broaden protection in such settings, particularly in Africa, where the Lewis-negative phenotype and P[6] rotavirus strains are common. The association between HBGA status and G3P[6] rotavirus vaccine (RV3-BB) take was investigated in a phase 2A study of RV3-BB vaccine involving 46 individuals in Dunedin, New Zealand, during 2012-2014. FUT2 and FUT3 genotypes were determined from DNA extracted from stool specimens, and frequencies of positive cumulative vaccine take, defined as an RV3-BB serum immune response (either immunoglobulin A or serum neutralizing antibody) and/or stool excretion of the vaccine strain, stratified by HBGA status were determined. RV3-BB produced positive cumulative vaccine take in 29 of 32 individuals (91%) who expressed a functional FUT2 enzyme (the secretor group), 13 of 13 (100%) who were FUT2 null (the nonsecretor group), and 1 of 1 with reduced FUT2 activity (i.e., a weak secretor); in 37 of 40 individuals (93%) who expressed a functional FUT3 enzyme (the Lewis-positive group) and 3 of 3 who were FUT3 null (the Lewis-negative group); and in 25 of 28 Lewis-positive secretors (89%), 12 of 12 Lewis-positive nonsecretors (100%), 2 of 2 Lewis-negative secretors, and 1 of 1 Lewis-negative weak secretor. RV3-BB produced positive cumulative vaccine take irrespective of HBGA status. RV3-BB has the potential to provide an improved level of protection in settings where P[6] rotavirus disease is endemic, irrespective of the HBGA profile of the population.
Sections du résumé
BACKGROUND
VP4 [P] genotype binding specificities of rotaviruses and differential expression of histo-blood group antigens (HBGAs) between populations may contribute to reduced efficacy against severe rotavirus disease. P[6]-based rotavirus vaccines could broaden protection in such settings, particularly in Africa, where the Lewis-negative phenotype and P[6] rotavirus strains are common.
METHODS
The association between HBGA status and G3P[6] rotavirus vaccine (RV3-BB) take was investigated in a phase 2A study of RV3-BB vaccine involving 46 individuals in Dunedin, New Zealand, during 2012-2014. FUT2 and FUT3 genotypes were determined from DNA extracted from stool specimens, and frequencies of positive cumulative vaccine take, defined as an RV3-BB serum immune response (either immunoglobulin A or serum neutralizing antibody) and/or stool excretion of the vaccine strain, stratified by HBGA status were determined.
RESULTS
RV3-BB produced positive cumulative vaccine take in 29 of 32 individuals (91%) who expressed a functional FUT2 enzyme (the secretor group), 13 of 13 (100%) who were FUT2 null (the nonsecretor group), and 1 of 1 with reduced FUT2 activity (i.e., a weak secretor); in 37 of 40 individuals (93%) who expressed a functional FUT3 enzyme (the Lewis-positive group) and 3 of 3 who were FUT3 null (the Lewis-negative group); and in 25 of 28 Lewis-positive secretors (89%), 12 of 12 Lewis-positive nonsecretors (100%), 2 of 2 Lewis-negative secretors, and 1 of 1 Lewis-negative weak secretor.
CONCLUSIONS
RV3-BB produced positive cumulative vaccine take irrespective of HBGA status. RV3-BB has the potential to provide an improved level of protection in settings where P[6] rotavirus disease is endemic, irrespective of the HBGA profile of the population.
Identifiants
pubmed: 31763671
pii: 5640309
doi: 10.1093/infdis/jiz333
pmc: PMC7075413
doi:
Substances chimiques
Antibodies, Viral
0
Blood Group Antigens
0
Rotavirus Vaccines
0
Fucosyltransferases
EC 2.4.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1070-1078Informations de copyright
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
Biol Neonate. 2001 Feb;79(2):91-6
pubmed: 11223649
Leg Med (Tokyo). 2001 Mar;3(1):2-14
pubmed: 12935727
Lancet. 2007 Nov 24;370(9601):1757-63
pubmed: 18037080
Clin Infect Dis. 2016 Jan 1;62(1):11-18
pubmed: 26508510
PLoS One. 2013 Jul 19;8(7):e69557
pubmed: 23894502
Nat Commun. 2015 Jan 05;6:5907
pubmed: 25556995
Sci Rep. 2018 Aug 28;8(1):12961
pubmed: 30154494
Emerg Microbes Infect. 2017 Apr 12;6(4):e22
pubmed: 28400594
Virus Res. 2016 Jan 4;211:64-8
pubmed: 26454189
J Infect Dis. 2018 Jul 13;218(4):546-554
pubmed: 29790933
J Infect Dis. 2002 May 1;185(9):1335-7
pubmed: 12001052
N Engl J Med. 2006 Jan 5;354(1):23-33
pubmed: 16394299
Biomed Res Int. 2014;2014:573652
pubmed: 24783214
Nat Commun. 2018 Jul 6;9(1):2631
pubmed: 29980685
N Engl J Med. 2010 Jan 28;362(4):289-98
pubmed: 20107214
Lancet Infect Dis. 2015 Dec;15(12):1389-97
pubmed: 26318715
Genetics. 2001 Jun;158(2):747-56
pubmed: 11404338
Annu Rev Virol. 2014 Nov;1(1):285-306
pubmed: 26958723
Emerg Infect Dis. 2015 Nov;21(11):2055-8
pubmed: 26488868
J Virol. 2000 Jul;74(14):6368-76
pubmed: 10864647
Clin Infect Dis. 2019 Sep 27;69(8):1313-1319
pubmed: 30561537
J Virol. 2012 May;86(9):4833-43
pubmed: 22345472
Vox Sang. 1995;69(3):166-82
pubmed: 8578728
Sci Rep. 2018 Jan 24;8(1):1502
pubmed: 29367698
Am J Hum Genet. 1996 Aug;59(2):343-50
pubmed: 8755920
Trans R Soc Trop Med Hyg. 1978;72(6):664-5
pubmed: 734729
N Engl J Med. 1983 Jul 14;309(2):72-6
pubmed: 6304516
Transfusion. 1999 Sep;39(9):1013-7
pubmed: 10533829
Vaccine. 2012 Apr 27;30 Suppl 1:A86-93
pubmed: 22520142
PLoS Negl Trop Dis. 2011 Dec;5(12):e1413
pubmed: 22216364
J Virol. 2006 Feb;80(3):1513-23
pubmed: 16415027
J Virol. 2012 Dec;86(24):13456-66
pubmed: 23035213
Pak J Biol Sci. 2017;20(2):59-69
pubmed: 29022996
JAMA Pediatr. 2015 Nov;169(11):1040-5
pubmed: 26389824
J Infect Dis. 2018 Apr 11;217(9):1399-1407
pubmed: 29390150
Epidemiol Infect. 2011 Jun;139(6):895-909
pubmed: 20707941
Biochem J. 1995 Dec 1;312 ( Pt 2):329-32
pubmed: 8526839
J Infect Dis. 2017 Mar 1;215(5):786-789
pubmed: 28329092
Virology. 1991 Apr;181(2):553-63
pubmed: 1849677
J Infect Dis. 2014 Apr 15;209(8):1227-30
pubmed: 24277741
J Infect Dis. 2019 Feb 15;219(5):746-749
pubmed: 30357332
Science. 1993 Dec 17;262(5141):1892-5
pubmed: 8018146
Mol Biol Evol. 2009 Sep;26(9):1993-2003
pubmed: 19487333
Clin Infect Dis. 2014 Dec 1;59(11):1567-73
pubmed: 25097083